Geode Capital Management’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
Geode Capital Management's SMMT Position: Q3 2026 in Review
Geode Capital Management increased its Summit Therapeutics (SMMT) stake by 1.8% in Q3 2026, buying an estimated $927K and bringing the position to 3,489,224 shares worth $59M. The position accounts for ﹤0.01% of the portfolio, ranked #1506.
Geode Capital Management first reported a position in SMMT in Q2 2020 and has held it in 26 quarters since. The position peaked at $67.9M in Q3 2024. 294 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- Geode Capital Management held 3,489,224 shares of Summit Therapeutics worth $59M as of Q3 2026.
- Geode Capital Management bought 61,961 Summit Therapeutics shares in Q3 2026, an estimated $927K.
- Summit Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #1506 holding.
- Geode Capital Management first reported a position in Summit Therapeutics in Q2 2020 and has held it in 26 quarters since.
- Geode Capital Management's Summit Therapeutics position peaked at $67.9M in Q3 2024.
- 294 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.